CSIMarket
 


Musclepharm Corporation  (MSLP)
Other Ticker:  
 
 

MSLP's Income from Cont. Operations Growth by Quarter and Year

Musclepharm's Income from Cont. Operations results by quarter and year




MSLP Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -6.78 2.82 -3.46
III Quarter September - -3.93 0.68 -5.08
II Quarter June - -2.25 -0.25 -5.88
I Quarter March -6.30 0.09 -0.06 -4.51
FY   -6.30 -12.87 3.19 -18.93



MSLP Income from Cont. Operations first quarter 2022 Y/Y Growth Comment
Musclepharm Corporation in the first quarter 2022 recorded loss from continued operations of $ -6.30 millions.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Income from Cont. Operations growth. While Musclepharm Corporation' s Income from Cont. Operations no change of % ranks overall at the positon no. 1382 in the first quarter 2022.




MSLP Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Musclepharm's first quarter 2022 Income from Cont. Operations $ -6.30 millions MSLP's Income Statement
Musclepharm's first quarter 2021 Income from Cont. Operations $ 0.09 millions Quarterly MSLP's Income Statement
New: More MSLP's historic Income from Cont. Operations Growth >>


MSLP Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - 314.71 % -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - -96.81 % - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #99
Overall #1382

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #99
Overall #1382
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Musclepharm's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MSLP's I. Quarter Q/Q Income from Cont. Operations Comment
Even if Musclepharm Corporation in the I. Quarter 2022 admitted loss from continued operations of $ -6.30 millions, it should be mentioned, that those numbers are slight up side relative to the -6.78 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Musclepharm Corporation achieved highest sequential Income from Cont. Operations growth. While Musclepharm's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MSLP's I. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Musclepharm Corporation in the I. Quarter 2022 revealed loss from continued operations of $ -6.30 millions, some analyst point out, that current results are recovery relative to the -6.78 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Musclepharm Corporation achieved highest sequential Income from Cont. Operations growth. While Musclepharm's Income from Cont. Operations growth quarter on quarter, overall rank is .


Musclepharm's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -19.26 $ -12.87 $ -3.27 $ 1.34 $ 3.34
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - -59.84 % 4.84 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 1390 # 0 # 0 # 2092 # 1385




Cumulative Income from Cont. Operations growth Comment
Musclepharm Corporation realized trailing twelve months loss from continued operations of $ -19 millions, in the Mar 31 2022, compare to Income from Cont. Operations of $ 3 millions a year ago.

Musclepharm Corporation achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
-503.96 %
-1114.2 %
-2391.01 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 99
S&P 500 # 1390
Cumulative Income from Cont. Operations growth Comment
Musclepharm Corporation realized trailing twelve months loss from continued operations of $ -19 millions, in the Mar 31 2022, compare to Income from Cont. Operations of $ 3 millions a year ago.

Musclepharm Corporation achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
-503.96 %
-1114.2 %
-2391.01 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 99
S&P 500 # 1390




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
MSLP's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for MSLP's Competitors
Income from Cont. Operations Growth for Musclepharm's Suppliers
Income from Cont. Operations Growth for MSLP's Customers

You may also want to know
MSLP's Annual Growth Rates MSLP's Profitability Ratios MSLP's Asset Turnover Ratio MSLP's Dividend Growth
MSLP's Roe MSLP's Valuation Ratios MSLP's Financial Strength Ratios MSLP's Dividend Payout Ratio
MSLP's Roa MSLP's Inventory Turnover Ratio MSLP's Growth Rates MSLP's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2022
Chemed Corporation-1.88%$ -1.882 millions
Biomx Inc -2.77%$ -2.773 millions
Ironwood Pharmaceuticals inc -2.82%$ -2.818 millions
Corcept Therapeutics Inc-2.85%$ -2.847 millions
Msa Safety Incorporated-2.89%$ -2.891 millions
Merit Medical Systems Inc-3.77%$ -3.769 millions
Addus Homecare Corporation-4.77%$ -4.767 millions
Idexx Laboratories Inc-5.05%$ -5.054 millions
Hca Healthcare Inc -7.28%$ -7.278 millions
National Research Corporation-7.51%$ -7.506 millions
Amgen Inc -10.33%$ -10.328 millions
Organon and Co -11.90%$ -11.899 millions
Regeneron Pharmaceuticals Inc -12.71%$ -12.706 millions
Blueriver Acquisition Corp -14.64%$ -14.638 millions
Intuitive Surgical Inc -15.12%$ -15.119 millions
Globus Medical Inc -15.98%$ -15.983 millions
Encompass Health Corporation-17.09%$ -17.093 millions
Molecular Templates inc -19.30%$ -19.296 millions
Royalty Pharma Plc-19.43%$ -19.434 millions
3m Company-19.91%$ -19.914 millions
Natus Medical Inc-20.58%$ -20.576 millions
Fulgent Genetics Inc -23.49%$ -23.486 millions
Quest Diagnostics Inc-23.88%$ -23.878 millions
Fonar Corporation-24.12%$ -24.122 millions
Hologic Inc-26.49%$ -26.488 millions
Integra Lifesciences Holdings Corp-27.52%$ -27.521 millions
Universal Health Services Inc -27.77%$ -27.765 millions
National Healthcare Corp-27.97%$ -27.966 millions
Incyte Corporation-29.03%$ -29.033 millions
Davita Inc -29.44%$ -29.439 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com